Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Depreciation and Depletion (2018 - 2025)

Organogenesis Holdings has reported Depreciation and Depletion over the past 8 years, most recently at $4.1 million for Q4 2025.

  • Quarterly results put Depreciation and Depletion at $4.1 million for Q4 2025, up 12.48% from a year ago — trailing twelve months through Dec 2025 was $15.3 million (up 12.11% YoY), and the annual figure for FY2025 was $15.3 million, up 12.11%.
  • Depreciation and Depletion for Q4 2025 was $4.1 million at Organogenesis Holdings, up from $4.0 million in the prior quarter.
  • Over the last five years, Depreciation and Depletion for ORGO hit a ceiling of $4.1 million in Q4 2025 and a floor of $1.0 million in Q1 2021.
  • Median Depreciation and Depletion over the past 5 years was $2.6 million (2023), compared with a mean of $2.5 million.
  • Biggest five-year swings in Depreciation and Depletion: dropped 24.83% in 2022 and later skyrocketed 100.0% in 2023.
  • Organogenesis Holdings' Depreciation and Depletion stood at $1.8 million in 2021, then fell by 14.51% to $1.5 million in 2022, then surged by 96.96% to $3.0 million in 2023, then grew by 21.23% to $3.6 million in 2024, then increased by 12.48% to $4.1 million in 2025.
  • The last three reported values for Depreciation and Depletion were $4.1 million (Q4 2025), $4.0 million (Q3 2025), and $3.7 million (Q2 2025) per Business Quant data.